Merck & Company, Inc. Press Releases

MRK 
$57.98
*  
0.10
0.17%
Get MRK Alerts
*Delayed - data as of Mar. 5, 2015  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Merck to Present at the 33rd Annual J.P. Morgan Healthcare Conference
1/9/2015 8:00:00 AM - Business Wire
▼-7.90 % Price Change since this news event. The Volume Ratio is 0.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck to Hold Fourth-Quarter and Full-Year 2014 Sales and Earnings Conference Call on February 4
1/5/2015 8:00:00 AM - Business Wire
▲0.57 % Price Change since this news event. The Volume Ratio is 3.24.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck Begins Tender Offer to Acquire Cubist
12/19/2014 8:00:00 AM - Business Wire
▼-1.73 % Price Change since this news event. The Volume Ratio is 1.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers
12/18/2014 7:30:00 AM - Business Wire
▼-0.03 % Price Change since this news event. The Volume Ratio is 1.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health
12/10/2014 9:30:00 AM - Business Wire
▼-3.04 % Price Change since this news event. The Volume Ratio is 1.29.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer
12/10/2014 8:45:00 AM - Business Wire
▼-3.67 % Price Change since this news event. The Volume Ratio is 1.28.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium
12/10/2014 8:30:00 AM - Business Wire
▼-3.35 % Price Change since this news event. The Volume Ratio is 1.28.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck Statement Regarding CUBICIN Patent Litigation
12/9/2014 8:11:00 AM - Business Wire
▼-4.09 % Price Change since this news event. The Volume Ratio is 2.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day










Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
12/8/2014 7:00:00 AM - Business Wire
▼-5.89 % Price Change since this news event. The Volume Ratio is 1.54.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting
12/6/2014 1:00:00 PM - Business Wire
▼-5.89 % Price Change since this news event. The Volume Ratio is 1.5.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day